These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6464128)

  • 21. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathobiology of Lassa fever.
    Buckley SM; Casals J
    Int Rev Exp Pathol; 1978; 18():97-136. PubMed ID: 350792
    [No Abstract]   [Full Text] [Related]  

  • 25. Current research for a vaccine against Lassa hemorrhagic fever virus.
    Warner BM; Safronetz D; Stein DR
    Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lassa fever: implications of T-cell immunity for vaccine development.
    ter Meulen J
    J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
    Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
    Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some tolerance for fur--animal studies in PLoS Medicine.
    The
    PLoS Med; 2005 Jun; 2(6):e203. PubMed ID: 15971961
    [No Abstract]   [Full Text] [Related]  

  • 31. Lassa fever: epidemiology, therapy and vaccine development.
    McCormick JB
    Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():353-66. PubMed ID: 3138361
    [No Abstract]   [Full Text] [Related]  

  • 32. [Characteristics of the immune response in mice immunized with the inactivated Lassa virus].
    Ignat'ev GM; Golubev VP; Godneva AT; Petkevich AS; Torop AV
    Vopr Virusol; 1989; 34(2):213-6. PubMed ID: 2474905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.
    Jahrling PB; Peters CJ
    Infect Immun; 1984 May; 44(2):528-33. PubMed ID: 6715049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The dynamics of the formation of IgG subclasses in Balb/c and CBA mice infected with the LCM, Lassa and Mopeia viruses and their role in diagnosis].
    Zaĭtseva VN; Bystrova SI; Shkolina TV; Vladyko AS
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (1):47-51. PubMed ID: 9221657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.
    Jahrling PB
    J Med Virol; 1983; 12(2):93-102. PubMed ID: 6619814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lassa virus.
    Günther S; Lenz O
    Crit Rev Clin Lab Sci; 2004; 41(4):339-90. PubMed ID: 15487592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lassa fever virus: properties and characteristics.
    Tomori O; Fabiyi A
    Niger Med J; 1979 Jan; 9(1):17-9. PubMed ID: 111436
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
    Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Ippy as a Lassa-fever-related virus.
    Swanepoel R; Leman PA; Shepherd AJ; Shepherd SP; Kiley MP; McCormick JB
    Lancet; 1985 Mar; 1(8429):639. PubMed ID: 2857974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.